SARS-CoV-2 Peptide Epitopes for Antibody Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing and managing COVID-19 lack precision in identifying SARS-CoV-2 infection and predicting disease severity, due to limitations in detecting specific antibodies and understanding immune responses.
Innovation Solution
The development of peptide epitope-based methods using VirScan technology to map SARS-CoV-2 epitopes, enabling high-throughput antibody detection and differentiation between infected and non-infected individuals, as well as identifying correlates of disease severity through machine learning models and epitope-specific assays.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional antibody detection methods are used, then the detection process is simple, but the measurement precision and ability to distinguish specific SARS-CoV-2 antibodies is insufficient
Solution Approach 1:
The patent segments the SARS-CoV-2 virus into multiple peptide epitopes (linear and conformational) that can be individually detected. By dividing the viral protein structure into distinct epitopic regions, the assay can precisely identify antibodies targeting specific viral components, thereby improving measurement precision while managing complexity through modular epitope design
Solution Approach 2:
The patent introduces peptide epitopes as intermediary elements between the antibody and the detection system. These epitopes serve as mediators that specifically bind to SARS-CoV-2 antibodies, enabling precise detection through their unique binding characteristics. The epitopes act as bridges that translate complex antibody-antigen interactions into measurable signals
2Reliability
If comprehensive epitope mapping is performed to identify all SARS-CoV-2 antibodies, then the diagnostic accuracy improves, but the time and resources required increase significantly
Solution Approach 1:
The patent performs preliminary action by pre-identifying and characterizing multiple SARS-CoV-2 epitopes before clinical deployment. The epitope library is prepared in advance with known binding specificities, allowing rapid screening of patient samples against this pre-established reference framework. This preliminary epitope mapping enables quick and reliable diagnosis without requiring time-consuming de novo characterization during patient testing
Solution Approach 2:
The patent employs partial action by selecting a representative subset of key epitopes that capture the essential immune response to SARS-CoV-2. Rather than analyzing every possible epitope, the assay focuses on immunodominant and functionally relevant epitopic regions, achieving sufficient diagnostic reliability with reduced testing complexity and faster turnaround time
3Productivity
If high-throughput epitope-specific assays are developed, then the productivity of antibody screening increases, but the device complexity and manufacturing difficulty increase
Solution Approach 1:
The patent uses copying by synthesizing multiple copies of defined peptide epitope sequences through recombinant DNA technology and expression systems. These replicated epitope copies are produced in large quantities with consistent quality, enabling high-throughput screening. The standardized epitope copies can be manufactured reproducibly across different batches and facilities, improving ease of manufacture while maintaining high productivity
Solution Approach 2:
The patent applies parameter changes by optimizing epitope length, amino acid composition, and chemical modification states to enhance binding affinity and stability. By carefully tuning these parameters, the assay achieves high sensitivity and specificity while using readily manufacturable peptide formats. The optimized epitope parameters balance diagnostic performance with manufacturing feasibility
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These methods provide accurate and sensitive detection of SARS-CoV-2 antibodies, enabling effective diagnosis and prognosis, and inform the development of targeted vaccines and therapies by elucidating immune responses and epitope-specific antibody functions.
Implementation Method 1
contacting the sample with one, two, or more, e.g., 1, 2, 3, 4, 5, 8, 10, 12, 15, 20, 25, 30, 50, 75, 80, 100, 150, 200, 250, 300, 350, 400, 500, 600, 700, 800, or more, peptides comprising 4 or more consecutive amino acids from a SARS-CoV-2 epitope sequence shown herein, under conditions sufficient for binding of antibodies in the sample to the peptides
Data Source
AI summary
Peptide epitopes identified in subjects infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and methods of use thereof for diagnosing, determining prognosis, and treating Coronavirus Disease 2019 (COVID-19), and developing prophylactic or therapeutic vaccines against SARS-CoV-2.